Elephas

Colossal Accelerates Research and Development of Life-Saving Vaccine to Prevent Elephant Extinction

Retrieved on: 
Wednesday, October 5, 2022
Technology, Biotechnology, Health, Environmental Issues, Professional Services, Environmental, Social and Governance (ESG), Other Philanthropy, Philanthropy, Other Science, Environment, Other Technology, Research, Genetics, Science, Genetic code, Houston Zoo, Disease, RNA transfection, Life, Elephas, EEHV, Virology, Genetic engineering, Research, List of life sciences, Baylor University, Mammoth, Multimedia, VGP, Partnership, Technology, Biodiversity, Department, Health, African bush elephant, CRISPR, Genetics, Elephant, New product development, Vertebrate Genomes Project, Death, Baylor College of Medicine, Hunting, African elephant, Barn, Colossal

Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.

Key Points: 
  • Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.
  • Colossal will lead the development of novel treatments and a vaccine to prevent the deadly disease and protect as many elephants as possible - both in zoos and in their natural habitats.
  • Colossal and Dr. Lings lab will accelerate milestones in three phases, including the development and rollout of a protein subunit vaccine, the development of an mRNA vaccine, and the development of a monoclonal antibody treatment.
  • Were thrilled to advance science to benefit both existing and future generations of elephants and mammoths, said Justin Quinn, Colossal Director of Product Development.

The Former Director of the Center for Drug Evaluation and Research at FDA, Steven Galson, Joins Elephas as Independent Director

Retrieved on: 
Thursday, July 28, 2022
Association, Executive Committee, Harvard School of Dental Medicine, BioCryst Pharmaceuticals, Icahn School of Medicine at Mount Sinai, Clinical trial, Center, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Center for Drug Evaluation and Research, Drug discovery, CEO, Stony Brook University, Artificial intelligence, National academy, Amgen, Board, Drexel University School of Public Health, Multimedia, Keck Graduate Institute, Cancer, Insilico Medicine, Medal, Leadership, Director, Drug development, FDA, CDER, Patient, LinkedIn, Commission, Surgeon, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Hope, Face, Public service, Popular Executive Committee of Valencia, National Academy of Medicine, Pharmaceutical industry, Research, Elephas

Dr. Galson is a consultant to Amgen and serves on the Board of Directors of Insilico Medicine and Biocryst Pharmaceuticals.

Key Points: 
  • Dr. Galson is a consultant to Amgen and serves on the Board of Directors of Insilico Medicine and Biocryst Pharmaceuticals.
  • "I chose to join Elephas because they are developing a platform that will increase access to effective cancer therapies.
  • I am excited to help a team focused on making a positive difference in cancer patients' lives," stated Dr. Galson.
  • Previously, he served as Director of the FDA's Center for Drug Evaluation and Research (CDER), where he provided leadership for the center's broad national and international programs in pharmaceutical regulation.

Colossal Biosciences and the Vertebrate Genomes Project Sequence the Asian Elephant Genome, Chromosome to Chromosome

Retrieved on: 
Tuesday, July 12, 2022
Technology, Research, Genetics, Other Technology, Software, Biotechnology, Health, Other Science, Science, Borneo, Forest, Technology, Howard Hughes Medical Institute, Bird, Disease, Life, African bush elephant, Multimedia, IUCN, News, Biology, Amphibian, Reptile, Vertebrate Genomes Project, African elephant, Genomics, Risk, Human genome, Fish, Gaps, CEO, Human, Woolly mammoth, Arima, Biodiversity, Elephant, Elephas, Publication, Rockefeller University, Genome, Vertebrate, Health, Mammal, List of life sciences, Genetic code, Climate change, Software, Doctor of Philosophy, DNA, Earth BioGenome Project, Agriculture, Antibiotics, Hunting, VGP, Colossal

Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP ) have become the first to successfully sequence the entire Asian elephant genome, introducing a new wave of innovative and disruptive animal conservation.

Key Points: 
  • Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP ) have become the first to successfully sequence the entire Asian elephant genome, introducing a new wave of innovative and disruptive animal conservation.
  • View the full release here: https://www.businesswire.com/news/home/20220712005534/en/
    Arima Hi-C Assembly of the Asian Elephant (Elephas maximus) Genome.
  • The first phase of this landmark project which was completed in June included the sequencing, assembly, and annotation of the Asian elephant (Elephas maximus) genome.
  • Following the efforts given to the T2T human genome project, the Asian elephant will be one of the first genomes to be sequenced T2T.

 Elephas to Show First Data on Breakthrough Oncology Diagnostics Platform at American Association for Cancer Research

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, FDA, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, AACR, American Association for Cancer Research, Family, Friends, Drug development, Camelidae, Research, Health, LTF, Movement, Cancer, Education, Multiphoton lithography, Ipilimumab, Artificial intelligence, Martek Biosciences Corporation, Science, Patient, Reading, Neoplasm, American Association, 2021 Essex County Council election, Technology, 3D, Immunotherapy, Association, Nivolumab, CEO, Diagnosis, LinkedIn, Medical imaging, Pharmaceutical industry, Elephas, Elephas, AACR, ELEPHAS, AACR

Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the acceptance of three abstracts by the American Association for Cancer Research (AACR).

Key Points: 
  • Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the acceptance of three abstracts by the American Association for Cancer Research (AACR).
  • The Elephas mission is to change the view of cancer and get the right treatment regimens to patients more quickly.
  • With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients.
  • The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.

Bringing them back from the brink of extinction

Retrieved on: 
Tuesday, October 12, 2021
Critically Endangered, Threatened species, Biology, Attention, Wildlife Conservation Society, Elephant, University, Elephas, WCI, Inbreeding, Survival, Time, Industry, Population, Human, Rainforest, Giant, IPB University, Habitat, Forestry, Mammal, Awareness, IUCN, Observation, International trade, Faculty, Agriculture, Intelligence, SECI, Biodiversity, Social behavior, Gadjah Mada University, Convention, IEP, Hunting

Besides their extraordinary appearance, their intelligence and social behavior has also made them an intriguing subject for observation.

Key Points: 
  • Besides their extraordinary appearance, their intelligence and social behavior has also made them an intriguing subject for observation.
  • "Habitat loss continues to be the number one threat to the survival of the Sumatran elephant," Mossbrucker said.
  • Through his book, Mossbrucker aims to raise awareness of the significance of the Sumatran elephant and the conservation efforts to bring them back from the brink of extinction.
  • Run by the Wildlife Conservation International (WCI) Board, IEP was formed to conserve elephants' entire ecosystems in a holistic manner.

Colossal Biosciences and the Vertebrate Genomes Project Will Preserve the Genetic Code of all Endangered Elephant Species Through Genomic Sequencing

Retrieved on: 
Friday, October 1, 2021
Veterinary, Environment, Research, Genetics, Philanthropy, Biotechnology, Health, Other Philanthropy, Science, Publication, Biodiversity, CRISPR, Bird, DNA, Vertebrate Genomes Project, Population, African bush elephant, Reptile, Biology, CEO, Genomics, Vertebrate, Life, Elephas, Disease, Earth BioGenome Project, Howard Hughes Medical Institute, Risk, Technology, Elephant, Genetic engineering, Research, Fish, Genetic code, Mammal, Amphibian, Doctor of Philosophy, De-extinction, Rockefeller University, IUCN, Antibiotics, Hunting

Colossal and the Vertebrate Genomes Project (VGP) embark on the worlds first effort to obtain the genetic code of the existing elephant lineage, of which all three species are endangered.

Key Points: 
  • Colossal and the Vertebrate Genomes Project (VGP) embark on the worlds first effort to obtain the genetic code of the existing elephant lineage, of which all three species are endangered.
  • Following the VGP principles, these genomes will be made publicly available to be used for research without use restrictions.
  • The Asian and African elephants are classified as Endangered, and the Forest elephant is classified as Critically Endangered by the IUCN .
  • By sequencing these three elephant species, we will genetically preserve the entire order.